Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major venous thromboembolism markets reached a value of US$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.
The venous thromboembolism market has been comprehensively analyzed in IMARC's new report titled "Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Venous thromboembolism refers to a life-threatening medical disorder characterized by the formation of blood clots within the veins, leading to the obstruction of blood flow. This disease mainly encompasses two primary conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in one of the deep veins, typically in the arms or legs, whereas PE develops if a blood clot dislodges from its site of origin and travels to the lungs, blocking one of the pulmonary arteries. Individuals suffering from this ailment may experience swelling, redness and warmth in the affected limb, chest pain, shortness of breath, rapid heart rate, lightheadedness, loss of consciousness, blood in the cough, etc. The diagnosis of venous thromboembolism typically involves a combination of clinical evaluation, medical history assessment, and blood analysis. A D-dimer test is utilized to detect an elevated level of a protein fragment that may be indicative of the disease. Several other diagnostic procedures, such as MR venography, vascular ultrasound, pulse oximetry, etc., are also performed to confirm a diagnosis among patients.
The rising prevalence of chronic injuries to veins or surrounding tissues that can disrupt blood flow and trigger clot formation is primarily driving the venous thromboembolism market. In addition to this, the increasing incidences of several associated risk factors, such as prolonged immobility, recent surgery or trauma, obesity, certain inherited blood clotting disorders, etc., are also bolstering the market growth. Moreover, the widespread adoption of direct oral anticoagulants, including apixaban, rivaroxaban, dabigatran, etc., which work by inhibiting the clotting factors in the blood, thereby preventing the formation of new clots, is further creating a positive outlook for the market. Besides this, the emerging popularity of inferior vena cava filters in patients who are unable to take pharmacological medicines is also propelling the market growth. This procedure involves the insertion of a tiny device into the large vein in the abdomen to prevent blood clots from reaching the lungs. Additionally, the escalating utilization of percutaneous mechanical thrombectomy for better and quicker removal of clots in the affected vein is expected to drive the venous thromboembolism market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the venous thromboembolism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for venous thromboembolism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the venous thromboembolism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the venous thromboembolism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the venous thromboembolism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current venous thromboembolism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the venous thromboembolism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the venous thromboembolism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the venous thromboembolism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of venous thromboembolism across the seven major markets?
What is the number of prevalent cases (2018-2034) of venous thromboembolism by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of venous thromboembolism by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with venous thromboembolism across the seven major markets?
What is the size of the venous thromboembolism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of venous thromboembolism?
What will be the growth rate of patients across the seven major markets?
Venous Thromboembolism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for venous thromboembolism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the venous thromboembolism market?
What are the key regulatory events related to the venous thromboembolism market?
What is the structure of clinical trial landscape by status related to the venous thromboembolism market?
What is the structure of clinical trial landscape by phase related to the venous thromboembolism market?
What is the structure of clinical trial landscape by route of administration related to the venous thromboembolism market?
The venous thromboembolism market has been comprehensively analyzed in IMARC's new report titled "Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Venous thromboembolism refers to a life-threatening medical disorder characterized by the formation of blood clots within the veins, leading to the obstruction of blood flow. This disease mainly encompasses two primary conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in one of the deep veins, typically in the arms or legs, whereas PE develops if a blood clot dislodges from its site of origin and travels to the lungs, blocking one of the pulmonary arteries. Individuals suffering from this ailment may experience swelling, redness and warmth in the affected limb, chest pain, shortness of breath, rapid heart rate, lightheadedness, loss of consciousness, blood in the cough, etc. The diagnosis of venous thromboembolism typically involves a combination of clinical evaluation, medical history assessment, and blood analysis. A D-dimer test is utilized to detect an elevated level of a protein fragment that may be indicative of the disease. Several other diagnostic procedures, such as MR venography, vascular ultrasound, pulse oximetry, etc., are also performed to confirm a diagnosis among patients.
The rising prevalence of chronic injuries to veins or surrounding tissues that can disrupt blood flow and trigger clot formation is primarily driving the venous thromboembolism market. In addition to this, the increasing incidences of several associated risk factors, such as prolonged immobility, recent surgery or trauma, obesity, certain inherited blood clotting disorders, etc., are also bolstering the market growth. Moreover, the widespread adoption of direct oral anticoagulants, including apixaban, rivaroxaban, dabigatran, etc., which work by inhibiting the clotting factors in the blood, thereby preventing the formation of new clots, is further creating a positive outlook for the market. Besides this, the emerging popularity of inferior vena cava filters in patients who are unable to take pharmacological medicines is also propelling the market growth. This procedure involves the insertion of a tiny device into the large vein in the abdomen to prevent blood clots from reaching the lungs. Additionally, the escalating utilization of percutaneous mechanical thrombectomy for better and quicker removal of clots in the affected vein is expected to drive the venous thromboembolism market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the venous thromboembolism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for venous thromboembolism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the venous thromboembolism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the venous thromboembolism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the venous thromboembolism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current venous thromboembolism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the venous thromboembolism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the venous thromboembolism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the venous thromboembolism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of venous thromboembolism across the seven major markets?
What is the number of prevalent cases (2018-2034) of venous thromboembolism by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of venous thromboembolism by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with venous thromboembolism across the seven major markets?
What is the size of the venous thromboembolism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of venous thromboembolism?
What will be the growth rate of patients across the seven major markets?
Venous Thromboembolism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for venous thromboembolism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the venous thromboembolism market?
What are the key regulatory events related to the venous thromboembolism market?
What is the structure of clinical trial landscape by status related to the venous thromboembolism market?
What is the structure of clinical trial landscape by phase related to the venous thromboembolism market?
What is the structure of clinical trial landscape by route of administration related to the venous thromboembolism market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VENOUS THROMBOEMBOLISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VENOUS THROMBOEMBOLISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VENOUS THROMBOEMBOLISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VENOUS THROMBOEMBOLISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VENOUS THROMBOEMBOLISM - UNMET NEEDS
10 VENOUS THROMBOEMBOLISM - KEY ENDPOINTS OF TREATMENT
11 VENOUS THROMBOEMBOLISM - MARKETED PRODUCTS
11.1 List of Venous Thromboembolism Marketed Drugs Across the Top 7 Markets
11.1.1 Pradaxa (Dabigatran etexilate) - Boehringer Ingelheim
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bevyxxa (Betrixaban) - Alexion AstraZeneca Rare Disease
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson Pharmaceutical Research & Development
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VENOUS THROMBOEMBOLISM - PIPELINE DRUGS
12.1 List of Venous Thromboembolism Pipeline Drugs Across the Top 7 Markets
12.1.1 Abelacimab - Anthos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Isoquercetin - Quercis Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TRX1 - TeaRx
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VENOUS THROMBOEMBOLISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VENOUS THROMBOEMBOLISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VENOUS THROMBOEMBOLISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Venous Thromboembolism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Venous Thromboembolism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Venous Thromboembolism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Venous Thromboembolism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Venous Thromboembolism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Venous Thromboembolism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Venous Thromboembolism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Venous Thromboembolism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Venous Thromboembolism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Venous Thromboembolism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Venous Thromboembolism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Venous Thromboembolism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Venous Thromboembolism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Venous Thromboembolism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Venous Thromboembolism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Venous Thromboembolism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Venous Thromboembolism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Venous Thromboembolism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Venous Thromboembolism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Venous Thromboembolism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Venous Thromboembolism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Venous Thromboembolism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Venous Thromboembolism - Access and Reimbursement Overview
16 VENOUS THROMBOEMBOLISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VENOUS THROMBOEMBOLISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VENOUS THROMBOEMBOLISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VENOUS THROMBOEMBOLISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VENOUS THROMBOEMBOLISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VENOUS THROMBOEMBOLISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VENOUS THROMBOEMBOLISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VENOUS THROMBOEMBOLISM - UNMET NEEDS
10 VENOUS THROMBOEMBOLISM - KEY ENDPOINTS OF TREATMENT
11 VENOUS THROMBOEMBOLISM - MARKETED PRODUCTS
11.1 List of Venous Thromboembolism Marketed Drugs Across the Top 7 Markets
11.1.1 Pradaxa (Dabigatran etexilate) - Boehringer Ingelheim
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bevyxxa (Betrixaban) - Alexion AstraZeneca Rare Disease
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson Pharmaceutical Research & Development
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VENOUS THROMBOEMBOLISM - PIPELINE DRUGS
12.1 List of Venous Thromboembolism Pipeline Drugs Across the Top 7 Markets
12.1.1 Abelacimab - Anthos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Isoquercetin - Quercis Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TRX1 - TeaRx
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VENOUS THROMBOEMBOLISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VENOUS THROMBOEMBOLISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VENOUS THROMBOEMBOLISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Venous Thromboembolism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Venous Thromboembolism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Venous Thromboembolism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Venous Thromboembolism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Venous Thromboembolism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Venous Thromboembolism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Venous Thromboembolism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Venous Thromboembolism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Venous Thromboembolism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Venous Thromboembolism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Venous Thromboembolism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Venous Thromboembolism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Venous Thromboembolism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Venous Thromboembolism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Venous Thromboembolism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Venous Thromboembolism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Venous Thromboembolism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Venous Thromboembolism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Venous Thromboembolism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Venous Thromboembolism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Venous Thromboembolism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Venous Thromboembolism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Venous Thromboembolism - Access and Reimbursement Overview
16 VENOUS THROMBOEMBOLISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VENOUS THROMBOEMBOLISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VENOUS THROMBOEMBOLISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
